Corcept Therapeutics is a clinical-stage biopharmaceutical company focused on discovering and developing drugs that modulate the effects of cortisol, a hormone implicated in a range of severe metabolic, oncologic and psychiatric disorders. The company’s scientific platform centers on selectively targeting the glucocorticoid receptor to counteract the harmful consequences of excess cortisol, a strategy designed to address diseases with significant unmet medical needs.
The company’s flagship marketed product, Korlym (mifepristone), is approved in the United States for the treatment of hyperglycemia secondary to Cushing’s syndrome in patients who have type 2 diabetes or glucose intolerance and are not candidates for surgery. Beyond Korlym, Corcept is advancing a proprietary pipeline of selective glucocorticoid receptor modulators, most notably relacorilant. Relacorilant is under investigation in multiple clinical trials for indications including endogenous Cushing’s syndrome, platinum-resistant ovarian cancer and psychotic major depression, reflecting Corcept’s commitment to expanding therapeutic options where cortisol dysregulation plays a key role.
Founded in 1998 and headquartered in Redwood City, California, Corcept went public in 2012 to support its transition from research to commercialization. Since then, the company has built a specialized commercial organization in the United States and is pursuing regulatory filings and partnerships in Europe and other regions. Corcept collaborates with academic institutions, clinical research centers and regulatory authorities to advance its programs from proof of concept through pivotal trials.
Corcept is led by President and CEO Joseph K. Belanoff, M.D., who co-founded the company and has guided its scientific and strategic direction for more than two decades. Under his leadership, Corcept has established a multidisciplinary team of researchers, clinicians and commercial experts. The company continues to explore novel approaches to glucocorticoid receptor modulation with the goal of delivering transformative therapies for patients affected by debilitating cortisol-related disorders.
AI Generated. May Contain Errors.
Free CORT Stock Alerts